Osimertinib Plus Chemo Reduces Progression in EGFR-Positive NSCLC With Central Nervous System Metastases
Osimertinib (Tagrisso) plus chemotherapy reduced the risk for central nervous system (CNS) progression in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with CNS metastases, according to findings from the phase 3 FLAURA2 trial (NCT04035486) presented at the 2023 ESMO Congress.1 Ultimately, patients who received osimertinib with ch